OXYBUTYNIN CHLORIDE
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- OXYBUTYNIN CHLORIDE
- Generic name
- OXYBUTYNIN CHLORIDE
- Manufacturer
- PD-Rx Pharmaceuticals, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 8bd5dce0-d56a-4e64-8de7-e7cd7775526b
- SPL ID
- 5f515de1-14ee-c1c2-e063-6394a90a5a46
- Version
- 11
- Effective date
- 2026-11-02
- Source export date
- 2026-11-13
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:55:26
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 209025 | derived:openfda.application_number |
| application number | ANDA209025 | openfda.application_number | |
| brand name | OXYBUTYNIN CHLORIDE | openfda.brand_name | |
| generic name | OXYBUTYNIN CHLORIDE | openfda.generic_name | |
| manufacturer name | PD-Rx Pharmaceuticals, Inc. | openfda.manufacturer_name | |
| ndc | package | 72789-417-30 | openfda.package_ndc |
| ndc | package | 72789-417-90 | openfda.package_ndc |
| ndc | product | 72789-417 | openfda.product_ndc |
| ndc11 | package | 72789041730 | derived:openfda.package_ndc |
| ndc11 | package | 72789041790 | derived:openfda.package_ndc |
| rxcui | 863664 | openfda.rxcui | |
| spl id | 5f515de1-14ee-c1c2-e063-6394a90a5a46 | id | |
| spl set id | 8bd5dce0-d56a-4e64-8de7-e7cd7775526b | set_id | |
| unii | L9F3D9RENQ | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Angioedema of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, oxybutynin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS The safety and efficacy of oxybutynin chloride was evaluated in a total of 199 patients in three clinical trials. These participants were treated with oxybutynin chloride 5 to 20 mg/day for up to 6 weeks. Table 3 shows the incidence of adverse events judged by investigators to be at least possibly related to treatment and reported by at least 5% of patients. Table 3 Incidence (%) of Adverse Events Reported by ≥ 5% of Patients Using oxybutynin chloride (5 - 20 mg/day) Body System Adverse Event OXYBUTYNIN CHLORIDE Infections and Infestations Urinary tract infection 6.5% Psychiatric Disorders Insomnia 5.5% Nervousness 6.5% Nervous System Disorders Dizziness 16.6% Somnolence 14.0% Headache 7.5% Eye Disorders Blurred vision 9.6% Gastrointestinal Disorders Dry mouth 71.4% Constipation 15.1% Nausea 11.6% Dyspepsia 6.0% Renal and Urinary Disorders Urinary Hesitation 8.5% Urinary Retention 6.0% The most common adverse events reported by patients receiving oxybutynin chloride 5 to 20 mg/day were the expected side effects of anticholinergic agents. The incidence of dry mouth was dose-related. In addition, the following adverse events were reported by 1 to <5% of patients using oxybutynin chloride (5 to 20 mg/day) in all studies. Infections and Infestations: nasopharyngitis, upper respiratory tract infection, bronchitis, cystitis, fungal infection; Metabolism and Nutrition Disorders: fluid retention; Psychiatric Disorders: confusional state; Nervous System Disorders: dysgeusia, sinus headache; Eye Disorders: keratoconjunctivitis sicca, eye irritation; Cardiac Disorders: palpitations, sinus arrhythmia; Vascular Disorders: flushing; Respiratory, Thoracic and Mediastinal Disorders: nasal dryness, cough, pharyngolaryngeal pain, dry throat, sinus congestion, hoarseness, asthma, nasal congestion; Gastrointestinal Disorders: diarrhea, abdominal pain, loose stools, flatulence, vomiting, abdominal pain upper, dysphagia, aptyalism, eructation, tongue coated; Skin and Subcutaneous Tissue Disorders: dry skin, pruritis; Musculoskeletal and Connective Tissue Disorders: back pain, arthralgia, pain in extremity, flank pain; Renal and Urinary Disorders: dysuria, pollakiuria; General Disorders and Administration Site Conditions: fatigue, edema peripheral, asthenia, pain, thirst, edema; Investigations: blood pressure increased, blood glucose increased, blood pressure decreased; Injury, Poisoning, and Procedural Complications: fall. Postmarketing Surveillance Because postmarketing adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following additional adverse events have been reported from worldwide postmarketing experience with Oral oxybutynin chloride: Psychiatric Disorders: psychotic disorder, agitation, hallucinations, memory impairment; Nervous System Disorders: convulsions; Eye Disorders: cycloplegia, mydriasis, glaucoma; Cardiac Disorders: tachycardia, QT interval prolongation; chest discomfort; Gastrointestinal Disorders: decreased gastrointestinal motility; frequent bowel movements; Skin and Subcutaneous Tissue Disorders: rash, decreased sweating; Renal and Urinary Disorders: impotence; Reproductive System and Breast Disorders: Suppression of lactation; General Disorders and Administration Site Conditions: hypersensitivity reactions, including angioedema with airway obstruction, urticaria, and face edema; rare anaphylactic reactions requiring hospitalization for emergency treatment; Metabolism and Nutrition Disorders : anorexia; Respiratory, Thoracic and Mediastinal Disorders : dysphonia To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="100%"> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Body System</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">Adverse Event</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">OXYBUTYNIN CHLORIDE</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Infections and Infestations </td> <td styleCode="Rrule" valign="top"> Urinary tract infection </td> <td styleCode="Rrule" valign="top"> 6.5% </td> </tr> <tr styleCode="Botrule"> <td rowspan="2" styleCode="Lrule Rrule" valign="top"> Psychiatric Disorders </td> <td styleCode="Rrule" valign="top"> Insomnia </td> <td styleCode="Rrule" valign="top"> 5.5% </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Nervousness </td> <td styleCode="Rrule" valign="top"> 6.5% </td> </tr> <tr styleCode="Botrule"> <td rowspan="3" styleCode="Lrule Rrule" valign="top"> Nervous System Disorders </td> <td styleCode="Rrule" valign="top"> Dizziness </td> <td styleCode="Rrule" valign="top"> 16.6% </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Somnolence </td> <td styleCode="Rrule" valign="top"> 14.0% </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Headache </td> <td styleCode="Rrule" valign="top"> 7.5% </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Eye Disorders </td> <td styleCode="Rrule" valign="top"> Blurred vision </td> <td styleCode="Rrule" valign="top"> 9.6% </td> </tr> <tr styleCode="Botrule"> <td rowspan="4" styleCode="Lrule Rrule" valign="top"> Gastrointestinal Disorders </td> <td styleCode="Rrule" valign="top"> Dry mouth </td> <td styleCode="Rrule" valign="top"> 71.4% </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Constipation </td> <td styleCode="Rrule" valign="top"> 15.1% </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Nausea </td> <td styleCode="Rrule" valign="top"> 11.6% </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Dyspepsia </td> <td styleCode="Rrule" valign="top"> 6.0% </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> Renal and Urinary Disorders </td> <td styleCode="Rrule" valign="top"> Urinary Hesitation </td> <td styleCode="Rrule" valign="top"> 8.5% </td> </tr> <tr> <td styleCode="Lrule Rrule" valign="top"> </td> <td styleCode="Rrule" valign="top"> Urinary Retention </td> <td styleCode="Rrule" valign="top"> 6.0% </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.